Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentka musi wyrazić pisemną zgodę na udział w badaniu i wyrazić zgodę na udostępnienie danych medycznych.
- •Pacjentka musi mieć ukończone 18 lat.
- •Diagnoza raka piersi potwierdzona badaniem tkanki, wskazująca na obecność receptorów estrogenowych i/lub progesteronowych.
- •Rak piersi nie powinien reagować na lek HER2 (potwierdzone badaniami).
- •Stwierdzono nawrót raka piersi w okolicy piersi, pach lub klatki piersiowej.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
University of Alabama at Birmingham
Birmingham, United States
University of Arizona
Phoenix, United States
Orlando Health Cancer Institute
Orlando, United States
University of Illinois Cancer Center
Chicago, United States
Parkview Research Center
Fort Wayne, United States
University of Iowa Hospitals and Clinics
Iowa City, United States
Tufts Medical Center
Boston, United States
University of Michigan Health System
Ann Arbor, United States
University of Michigan Health-West
Wyoming, United States
University of Nebraska Medical Center
Omaha, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, United States
New York University Clinical Cancer Center
New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
Providence Portland Medical Center
Portland, United States
Penn State Cancer Institute
Hershey, United States
Medical University of South Carolina
Charleston, United States
University of Virginia Health System
Charlottesville, United States
Virginia Commonwealth University
Richmond, United States
University of Wisconsin
Madison, United States
Trial contact
Oana Danciu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.